Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.32 - $0.62 $6,451 - $12,499
20,160 Added 39.07%
71,755 $44,000
Q3 2023

Nov 14, 2023

SELL
$0.46 - $0.65 $5,953 - $8,412
-12,942 Reduced 20.05%
51,595 $24,000
Q2 2023

Aug 14, 2023

BUY
$0.57 - $1.08 $36,786 - $69,699
64,537 New
64,537 $38,000
Q4 2022

Feb 14, 2023

SELL
$1.1 - $2.45 $662,294 - $1.48 Million
-602,086 Reduced 69.37%
265,822 $329,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $7.38 Million - $12.5 Million
-3,762,856 Reduced 81.26%
867,908 $1.79 Million
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $1.69 Million - $3.62 Million
744,091 Added 19.14%
4,630,764 $12.8 Million
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $237,185 - $363,170
64,278 Added 1.68%
3,886,673 $17 Million
Q4 2021

Feb 14, 2022

SELL
$5.37 - $7.07 $3.65 Million - $4.81 Million
-680,406 Reduced 15.11%
3,822,395 $21.1 Million
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $694,577 - $941,566
125,375 Added 2.86%
4,502,801 $27.8 Million
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $723,983 - $1.06 Million
-93,057 Reduced 2.08%
4,377,426 $37.2 Million
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $5.18 Million - $8.58 Million
1,011,367 Added 29.24%
4,470,483 $35.4 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $903,447 - $2.01 Million
285,901 Added 9.01%
3,459,116 $20.1 Million
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $5.25 Million - $7.62 Million
1,610,408 Added 103.05%
3,173,215 $10.8 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $2.37 Million - $6.94 Million
1,499,790 Added 2379.98%
1,562,807 $7.21 Million
Q1 2020

May 15, 2020

BUY
$1.44 - $3.02 $37,978 - $79,649
26,374 Added 71.98%
63,017 $100,000
Q4 2019

Feb 14, 2020

SELL
$2.25 - $3.07 $56,868 - $77,594
-25,275 Reduced 40.82%
36,643 $100,000
Q3 2019

Nov 14, 2019

BUY
$2.67 - $3.65 $111,739 - $152,752
41,850 Added 208.54%
61,918 $182,000
Q2 2019

Aug 14, 2019

SELL
$2.6 - $4.21 $233,677 - $378,377
-89,876 Reduced 81.75%
20,068 $58,000
Q1 2019

May 15, 2019

BUY
$3.05 - $4.34 $234,993 - $334,383
77,047 Added 234.21%
109,944 $0
Q3 2018

Nov 13, 2018

SELL
$1.45 - $6.15 $10,857 - $46,051
-7,488 Reduced 18.54%
32,897 $0
Q4 2017

Feb 09, 2018

BUY
$1.23 - $2.3 $49,673 - $92,885
40,385
40,385 $53,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.